About Us

Powered by science. Fueled by collaboration.

Explore how our dedicated team pioneers viral-based gene therapy manufacturing technology to improve the lives of people with chronic health conditions.

Embracing Life. Delivering hope.

Welcome to FinVector, a leading cGMP manufacturer of viral-based products with a strong commitment to restoring hope, purpose and a true sense of belonging for those living with chronic health conditions.

Our state-of-the-art manufacturing facility is nestled in the thriving science and technology district of Savilahti, Kuopio, Finland, surrounded by stunning lakes and forests. This unique setting offers not only a dynamic work environment but also an exceptional quality of life.

FinVector has firmly established itself as a beacon of innovation in the cancer drug industry, gaining international recognition as a leader in Viral-Based Gene Therapy product manufacturing. Presently, FinVector produces a groundbreaking treatment for Non-Muscle Invasive Bladder Cancer, offering meaningful hope to countless patients worldwide.

Our work culture

Deliver for patients

Everything we do, we are driven by our commitment to improving the lives of people with chronic health conditions. We do this by excelling in the scientific manufacturing and delivery of viral-based gene therapy products with the highest standards of safety and efficacy.

Our mission is to deliver for patients.

Where science gives hope

We innovate at the forefront of technology and scientific expertise
We strive to be a global competence centre for viral-based gene therapy products
We improve people’s quality of life and give them hope
We are a people-first company

Putting people first

We firmly believe that the key to our success lies within our people and their unwavering dedication to their work and the well-being of others. We actively recruit talented individuals from across the globe, assembling a vibrant team of hundreds of highly skilled professionals.

Our inclusive international community allows our employees to collaborate with other world-class experts who share a passion for improving health outcomes through cutting-edge science and manufacturing technology. We have thoughtfully cultivated a friendly, supportive, and well-structured environment that benefits the company’s mission and fosters both professional and personal growth for our employees.

FinVector is a dedicated partner in the fight against cancer. As an FDA-approved drug manufacturer, we work together with a meticulous attention to detail that ensures patient safety. We also possess a comprehensive understanding of and strict adherence to regulatory compliance, enabling us to fulfil our mission of delivering top-tier solutions and treatments to our partners.

Few of our employees could have imagined being part of an ambitious company that develops life-saving cancer therapies, especially here in this laid-back, nature-rich region of Finland. We are immensely proud to have them on board, and we invite you to join us in this vital fight.

Board of Directors

Giuseppe Carloni

Chairman of the board

Mr. Carloni served as the Managing Director of FinVector from July 2020 to December 2021 and as BLA Approval Director & QU Director until 15 October 2022. After the FDA inspection, he became a member of the board of FinVector and as of 1st of July 2023, Giuseppe was nominated as the Chairman of the board.

Armin Metzger

Vice Chair, Board member

Dr. Metzger is currently working as as an Executive Vice President and Chief Technical Operations Officer at Ferring Pharmaceuticals.

Bipin Dalmia

Board member

Dr. Dalmia is currently working as Senior Vice President, Global Head, Uro-Oncology Franchise at Ferring Pharmaceuticals. Bipin is responsible for all aspects of the Uro-Oncology Franchise at Ferring which includes Adstiladrin. Immediately prior to his global franchise role, Bipin was responsible for all Ferring U.S. strategy, business development, and new product planning activities and was a member of the Ferring U.S. executive leadership team.

Wolfram Carius

Board member

Professor Dr. Carius is currently working as an Executive Vice President Cell and Gene Therapy in Bayer Pharmaceuticals. Wolfram has over 30 years of experience in Pharma and Biotech working in various countries such as Japan and the USA.

Jean-Frédéric Paulsen

Board member

Mr. Paulsen is currently an Executive Chairman of the Ferring Group. Previously, Jean-Frédéric has been Chairman of Ferring Ventures SA and FinVector Oy during 2020-2023.